Patients & Caregivers
Fibrolamellar Cancer Foundation Leads the Way During Liver Cancer Awareness Month
October is Liver Cancer Awareness month, and the Fibrolamellar Cancer Foundation is making sure the world's fifth most common cancer type is properly recognized.
FDA Fast Tracks Astellas' AML Treatment
This morning, Astellas announced that it was granted Fast Track designation for the development of gilternitinb in adult patients with AML.
Cancer Peptide Vaccine Earns Second Orphan Drug Designation of 2017
Boston Biomedical has announced that the FDA has granted orphan drug designation to DSP-7888, a vaccine for the treatment of patients with brain cancer.
Tagrisso Gets the Attention of the FDA
FDA granted Breakthrough Therapy Designation for Tagrisso
(osimertinib) as a first-line treatment for metastatic EGFR+ NSCLC.
Trovagene Gets FDA Orphan Drug Designation for AML Treatment
Trovagene, Inc. was granted Orphan Drug Designation from the U.S. Food and Drug Administration for its acute myeloid leukemia drug PCM-075.
Obinutuzumab Better Than Rituximab in Follicular Lymphoma Patients
Data from the GALLIUM Study that obinutuzumab-based immunochemotherapy and maintenance therapy is better for follicular lymphoma than rituximab-based therapy.
FDA Approves New Dosage for Rare Lung Cancer Drug
Patients with this rare lung cancer can now opt to orally ingest a 180 mg tablet
Clinical Advancements & Essential Resources for Women Fighting Ovarian Cancer
Clinical advancements in screening tests, surgical procedures, chemotherapy, etc are also helping to control this rare disease.
Pfizer Creates New Smaller Company to Focus on Rare Diseases
Pfizer announced plans for SpringWorks Therapeutics, which will be focused on just 4 experimental drugs, 3 of which are for rare diseases.
Merkel Cell Carcinoma Treatment Approved in Europe
The European Commission (EC) has approved the first-ever immunotherapy for the rare and aggressive skin cancer metastatic merkel cell carcinoma (mMCC).
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.